An Evidence-based, Individualized Approach to the Management of Gastrointestinal Malignancies
Tuesday, August 27, 2019
5:30 – 6:00 PM: Registration and Dinner
6:00 – 8:00 PM: Meeting
Chicago Marriott at Medical District/UCI
625 S Ashland Avenue at Harrison Street
Chicago, IL 60607
Meeting Room: Ballroom (lower level of the hotel. The Ballroom is accessible by either the stairs or elevator. When you walk into the lobby there are stairs just past the front desk.)
- iPads provided to enhance learning experience
- Interactive, Case-based learning environment
John L. Marshall, MD
Chief, Division of Hematology/Oncology
Medstar Georgetown University Hospital
Professor of Medicine and Oncology
Lombardi Comprehensive Cancer Center Georgetown University
Director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer
Daniel Catenacci, MD
Associate Professor, Department of Medicine, Section of Hematology & Oncology
Director, Interdisciplinary Gastrointestinal Oncology Program
Assistant Director, Translational Research, Comprehensive Cancer Center
The University of Chicago Medical Center & Biological Sciences
This activity is designed to meet the needs of medical oncologists, particularly community oncologists, oncology nurses, and other health care professionals involved in caring for patients with gastrointestinal cancers.
- Review evidence and guideline recommendations for optimally sequencing different treatment modalities across subsequent lines of therapy for advanced and metastatic gastric (GC) and gastroesophageal junction (GEJ) cancers.
- Discuss strategies to individualize therapy for advanced and metastatic GC and GEJ cancers based on patient’s characteristics and biomarkers across lines of treatment.
- Review the clinical evidence of the prognostic and predictive value of anatomical characteristics and biomarkers in guiding treatment selection for advanced and metastatic colorectal cancer (CRC) across lines of therapy.
- Review the biology of α-fetoprotein (AFP) in hepatocellular carcinoma (HCC); explain the clinical significance of elevated serum AFP; and discuss AFP’s role as a prognostic and predictive biomarker in HCC.
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 2.0 AMA Category 1 Credit(s)TM.
Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
This program would be beneficial for nurses involved in the care of patients with patients with gastrointestinal cancers.
2.0 ANCC Contact Hour(s)
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 2.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at email@example.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event Staff will be glad to assist you with any special needs (i.e. physical, dietary, etc.) Please contact Med Learning Group prior to the live event at firstname.lastname@example.org
Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.